This study reports on a group of 20 patients with an initial diagnosis of primary biliary cirrhosis (PBC) whose serum (AMA-IF).' In one series of 218 patients, nine were AMA-IF negative and seven of these were subsequently found to be AMA-IF positive when additional serum specimens were examined suggesting that less than 1% of PBC patients were negative for AMA-IF in this large study.4 The identification and purification of the major mitochondrial autoantigens has permitted immunoassays to be developed that are more sensitive than immunofluorescence techniques for the detection of AMA.5 In this study we report the clinical, serological, and histological features of patients initially thought to have PBC by all the accepted criteria except they proved to be AMA-IF negative. Our findings show that patients with AMA-negative PBC may have a syndrome immunologically distinct from AMA-positive PBC.
Abstract
This study reports on a group of 20 patients with an initial diagnosis of primary biliary cirrhosis (PBC) whose serum tested negative for antimitochondrial antibodies by immunofluorescence. All had a clinical history compatible with primary biliary cirrhosis, and results of biochemical, histological, and radiological investigations were consistent with this diagnosis despite the absence of antimitochondrial antibodies by immunofluorescence. For comparison, these patients were matched for sex and serum bilirubin with 20 antimitochondrial antibody positive (>1:160) and histologically confirmed primary biliary cirrhosis patients who served as controls. Serum samples from both groups were retested blindly for antimitochondrial antibodies using immunoblotting and for antibodies to the major M2 mitochondrial autoantigens by enzyme linked immunosorbent assay (ELISA). Three antimitochondrial antibody immunofluorescence negative patients had antimitochondrial antibodies by immunoblotting and ELISA; the remaining 17 patients were confirmed negative by all methods. The antimitochondrial antibody immunofluorescence positive controls were verified by immunoblotting or ELISA, or both. All 17 patients negative for antimitochondrial antibodies had antinuclear antibodies, often in high titres, compared with 3/17 ofthe antimitochondrial antibody positive controls (p=0O0001). Additionally, the antimitochondrial antibody negative group also had significantly higher smooth muscle antibody titres (p=003) and lower serum IgM (p=0.01) and aspartate aminotransferase (p=0.03) activities than the antimitochondrial antibody positive controls. Analysis of clinical findings, histological tests, serum bilirubin, alkaline phosphatase, alamine aminotransferase, and IgG, disclosed no significant differences between the two groups. This paper describes a group of patients with the clinical and histological features ofPBC but who do not fulfil the usual criteria necessary to make this diagnosis. Because Immunoblotting for PDC 2 20 Immunoblotting for OGDC 0 2
Immunoblotting for BCOADC (Table III) . Similarly, serum IgG, alkaline phosphatase, and alanine aminotransferase activities at the time of referral were not significantly different (Table IV) . The serum IgM and aspartate aminotransferase, however, were significantly lower in the AMA-IF negative group (p=001 and p=0-03 respectively).
The mean follow up time in the AMA-all negative and positive patients was 4-8 v 4-4 years (Fig 1) . Nodular lymphoid aggregates without germinal centres were seen in one biopsy specimen. Mild parenchymal lymphoid infiltration was present in seven specimens, often associated with focal There is evidence suggesting that AMA in the form of autoantibodies against the pyruvate dehydrogenase-E2 may be the T-cell epitope, which may initiate the T-cell response leading to biliary epithelial damage. Monoclonal mouse antibodies, which react to PDH-E2 produce distinct intense activity when used to stain bile ducts in patients with PBC in contrast with bile duct specimens from patients with primary sclerosing cholangitis and autoimmune chronic active hepatitis.32 Cloned T-cell lines have been generated from patients with PBC, but not from those with chronic aggressive hepatitis, which produce IL-2 specifically in response to PDH-E2. In contrast, our results suggest that the clinical and histological pattern typical of PBC is quite independent of any evidence of serum antibodies for AMA. This may signify that AMA play no part in the pathogenesis of PBC or that the clinical and histological features we would normally associate with AMA positive PBC are a non-specific response to an immune liver injury.
In conclusion, there are now several syndromes with features of apparent autoimmune liver injury including primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune chronic active hepatitis. Our 17 AMA-all negative patients were initially thought to have PBC based on their symptoms and histological tests. They did not have, however, the immune markers associated with PBC (AMA and raised IgM), two of four criteria commonly used to make the diagnosis of PBC. Instead they have antinuclear antibodies often at very high titres, smooth muscle antibodies, and comparatively low serum IgM and aspartate aminotransferase activities. We believe that these AMA-all negative patients have a form of autoimmune cholangitis distinct from that seen in AMA positive PBC and other autoimmune liver diseases, which may have a different pathogenesis. Further characterisation of the cause and pathogenesis of such patients will be necessary before this classification can be refined.
